Model-based drug discovery: implementation and impact

…, M Aurell, RDO Jones, VJA Schuck, AC Egnell… - Drug discovery today, 2013 - Elsevier
… Author links open overlay panel Sandra AG Visser 1 , Malin Aurell 2 , Rhys DO Jones 3 ,
Virna JA Schuck 4 , Ann-Charlotte Egnell 5 , Sheila A. Peters 6 , Lena Brynne 7 , James WT …

[HTML][HTML] Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes

…, LG Carlsson, C Arfvidsson, AC Egnell… - Nature …, 2019 - nature.com
Chemically modified mRNA is an efficient, biocompatible modality for therapeutic protein
expression. We report a first-time-in-human study of this modality, aiming to evaluate safety and …

[HTML][HTML] Biocompatible, purified VEGF-A mRNA improves cardiac function after intracardiac injection 1 week post-myocardial infarction in swine

…, F Gregoire, T Albery, M Billger, AC Egnell… - … Therapy-Methods & …, 2018 - cell.com
mRNA can direct dose-dependent protein expression in cardiac muscle without genome
integration, but to date has not been shown to improve cardiac function in a safe, clinically …

Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s

TE Bapiro, AC Egnell, JA Hasler… - Drug metabolism and …, 2001 - ASPET
In this study we have evaluated the application and reliability of using fluorescence (FLUO)-based
high throughput screening assays with recombinant CYPs (rCYP). This was …

In vivo CYP3A4 heteroactivation is a possible mechanism for the drug interaction between felbamate and carbamazepine

AC Egnell, B Houston, S Boyer - Journal of Pharmacology and Experimental …, 2003 - ASPET
Atypical (non-Michaelis-Menten) kinetics are commonly observed with CYP3A4 substrates in
vitro. If relevant in vivo, cytochrome P450 heteroactivation could give rise to increased drug …

Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dyslipidemia of insulin resistance

U Olsson, AC Egnell, MR Lee, GO Lundén… - Diabetes, 2001 - Am Diabetes Assoc
Insulin resistance and type 2 diabetes are associated with elevated circulating levels of
insulin, nonesterified fatty acids (NEFAs), and lipoprotein remnants. Extracellular matrix …

Generation and evaluation of a CYP2C9 heteroactivation pharmacophore

AC Egnell, C Eriksson, N Albertson, B Houston… - … of Pharmacology and …, 2003 - ASPET
Positive cooperativity (auto- and heteroactivation) of drug oxidation, a potential cause of
drug interactions, is well established in vitro for cytochrome P450 (P450) 3A4 but to a much …

Predictive models of CYP3A4 Heteroactivation: in vitro-in vivo scaling and pharmacophore modeling

AC Egnell, JB Houston, CS Boyer - Journal of Pharmacology and …, 2005 - ASPET
Although activation of CYP3A4 is frequently observed in vitro, predictive computational-based
models and methods for in vitro-in vivo scaling are scarce. It has been previously shown …

Discovery of AZD8165–a clinical candidate from a novel series of neutral thrombin inhibitors

…, J Bergman, U Bredberg, J Brĺnalt, AC Egnell… - …, 2016 - pubs.rsc.org
A novel series of neutral thrombin inhibitors has been developed using a selection process
based on docking experiments and property calculations and predictions. This work resulted …

Elliptic boundary value problems with singular coefficients and critical nonlinearities

H Egnell - Indiana University mathematics journal, 1989 - JSTOR
This type of problem has been studied in several papers. Let us mention some of them. The
case when m= 2 and v= 0 was first treated in a famous paper by Brezis and Nirenberg [BN], …